The FDA is raising the bar for approval of CAR T-cell therapies in oncology. | The FDA is raising the bar for approval of CAR ...
Topline final safety and efficacy results for the full 36 weeks of treatment from all participants will be available in ...
For traditional approval, CAR T therapies will need to establish superiority over current standard treatments, including ...
Modified endotracheal tubes designed to reduce patient pneumonia risk failed to improve outcomes compared to standard ...
Background The role of mineralocorticoid receptor antagonists (MRAs) in acute myocardial infarction (MI) remains ...
Publication of Interim Results and Presentation at Recent Industry Event Demonstrate Clinical Benefit Associated with Use of ...
Introduction Implementation of low-intensity, evidence-based psychological interventions can help meet the mental health and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback